Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer’s Disease

Nexalin Technology, the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announced the publication of additional positive clinical data in Radiology demonstrating that its proprietary 15 milliamp (mA) Gen-2 Nexalin DIFS™ technology—Nexalin’s advanced implementation of transcranial alternating current stimulation (tACS)—improves cognitive performance and enhances brain network connectivity in patients with mild Alzheimer’s disease (AD). The randomized, sham-controlled trial provides the strongest peer-reviewed evidence to date of a non-invasive, drug-free intervention delivering measurable neurological and clinical benefits in AD. Key Findings from the Clinical Study:

Clinically Meaningful Cognitive Gains: Patients receiving Nexalin’s Gen-2 SYNC 40-Hz DIFS device showed a significant improvement in Mini-Mental State Examination (MMSE) scores and additional significant improvement in Montreal Cognitive Assessment (MoCA) scores compared to baseline. These improvements were statistically significant when compared to the sham group (P = .001 and .03, respectively).

Neuroimaging-Confirmed Mechanism: Resting-state functional MRI (fMRI) revealed enhanced functional connectivity (FC) between the hippocampus and key cortical regions, including the middle cingulate gyrus and middle frontal gyrus, both of which are critical to memory and executive function.

Network-Level Effects: Statistically significant increases in FC were also observed across broader cognitive networks, including the default mode network (DMN), frontoparietal networks (FPN), and visual and auditory systems, which are commonly disrupted in Alzheimer’s disease.

Correlated Cognitive Gains: Increased connectivity between the hippocampus and middle cingulate gyrus was significantly correlated with improvement on the Boston Naming Test, providing further evidence of the link between brain network modulation and functional outcomes (r = 0.65, FDR-adjusted P = .008).

Excellent Safety Profile: No adverse events were reported during the treatment period, reinforcing the safety and tolerability of Nexalin’s DIFS technology.

“The results of this study represent a significant milestone for Nexalin’s technology platform,” said Mark White, CEO of Nexalin. “The data clearly supports our belief that Nexalin’s non-invasive deep, frequency-specific neurostimulation can meaningfully improve cognitive performance in patients with Alzheimer’s disease. With a global AD market projected to exceed $20 billion annually, these findings further strengthen our long-term strategy to deliver safe, and effective alternatives to pharmacologic treatments for neurodegenerative conditions and their associated costs and side effects.”

This study is the first to demonstrate fMRI confirmation, that a 40-Hz, 15 mA electrical waveform can increase hippocampal-cortical connectivity in AD patients and is associated with measurable cognitive improvement. These findings illuminate the mechanism of action underlying DIFS and further validate Nexalin’s efforts in neurostimulation for neurodegenerative diseases.